Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study.
Kai SunAmanda M EudyNathaniel HarrisDavid S PisetskyLisa G Criscione-SchreiberRebecca E SadunJayanth DossMegan E B ClowseJennifer L RogersPublished in: Journal of patient-reported outcomes (2023)
PROMIS-29 similarities in patients with high Type 2 SLE, with and without active Type 1 SLE, demonstrate the challenges of using PROs to assess SLE inflammation. In conjunction with the Type 1 and 2 SLE model, however, PROMIS-29 identified distinct symptom patterns, suggesting that the model may help clinicians interpret PROs.